BIIB
BiogenPrevious close
253.62
Change
+3.97 / +1.59%
P/E (TTM) ?
44.9
Market Cap
$37.4B
1M
+12.28%
S&P 500 −0.91% over same period
Volume / Avg Volume
1.3M / 1.4M
0.93× average
Latest earnings analysisFY2026 Q2Reported 2026-07-01
Biogen Q2 2026: revenue up 3.4%, non-GAAP EPS beats, guidance cut
Biogen's second quarter looks better underneath than on the surface: revenue of $2.74 billion rose 3.4% and non-GAAP EPS of $3.60 beat the $3.01 consensus, while reported guidance was cut to $12.00-$13.00 for deal charges. Neutral. Read the underlying business separately from the accounting noise from the Apellis deal, and watch whether gross margin and cash recover.
Read the full analysis →Revenue$2.74BYoY +3.40%
EPS (non-GAAP)$3.60Beatest. $3.01
Next-day move+3.04%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-07-01 | $2.7B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-06 | $2.5B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-01-14 | $9.9B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-14 | $2.5B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 100 of its 5-year rangeExpensive
5-year range 12.3 – 28.1 · Median 17.7
No buybacks or dividends in the last four quarters
P/E (TTM)
44.9
P/B
2.0
P/S
3.7
PEG
2.89
Earnings Reaction
Over the last 4 reports, the stock moved ±1.6% on average on the first trading day after, rising 2 times
Most recent +3.04%
Volatility & Correlation
1-year beta 0.24 · Correlation with S&P 500 0.09Low beta
Annualized volatility 34% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 2 · $0.24MNet selling $0.24M
- 08-04Minor LloydDirectorSell$0.12M593 shares · Avg price 200.96
- 08-03Minor LloydDirectorSell$0.12M593 shares · Avg price 203.34
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q3 | 2.80 | +10.6% | 73.3% | -0.02 | -0.14 |
| FY2026 Q2 | 2.74 | +3.4% | 71.6% | 0.10 | 0.66 |
| FY2026 Q1 | 2.48 | +1.9% | 73.3% | 0.32 | 2.15 |
| FY2025 Q4 | 2.28 | −7.1% | 78.3% | -0.05 | -0.35 |
| FY2025 Q3 | 2.53 | +2.8% | 73.4% | 0.47 | 3.17 |
| FY2025 Q2 | 2.65 | +7.3% | 77.1% | 0.63 | 4.33 |
| FY2025 Q1 | 2.43 | +6.1% | 74.1% | 0.24 | 1.64 |
| FY2024 Q4 | 2.45 | +2.9% | 76.2% | 0.27 | 1.82 |
| FY2024 Q3 | 2.47 | −2.5% | 74.1% | 0.39 | 2.66 |
| FY2024 Q2 | 2.46 | +0.4% | 77.8% | 0.58 | 4.00 |
| FY2024 Q1 | 2.29 | −7.0% | 76.3% | 0.39 | 2.70 |
| FY2023 Q4 | 2.39 | −6.2% | 74.1% | 0.25 | 1.70 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| BIIB | 44.9 | +10.6% | 73.3% | +12.28% | Neutral |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |